CRISPR Therapeutics AG
CRSP · XNASCIK 1674416fmd_1P4Z68KQ4HJ7G7B6WN1NKPHAB1Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2014 to Sep 30, 2026, 48 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 5 | 41 | 3 | 290 | 1 | 915 | 1 | 371 | 37 | 4 |
| Research and development | 42 | 70 | 114 | 179 | 221 | 341 | 462 | 387 | 310 | 285 |
| Total operating expenses | 73 | 106 | 162 | 243 | 355 | 541 | 674 | 594 | 504 | 668 |
| Operating income | (68) | (65) | (159) | 47 | (354) | 374 | (673) | (223) | (467) | (665) |
| Interest and investment income | – | – | – | – | – | – | 23 | 76 | 104 | – |
| Other non-operating income (expense) | 45 | (2) | (5) | 21 | 6 | 6 | 23 | 72 | 104 | 87 |
| Income before taxes | (23) | (67) | (164) | 67 | (348) | 380 | (651) | (151) | (363) | (578) |
| Income tax expense | 0 | 2 | 1 | 0 | 1 | 2 | (0) | 3 | 4 | 4 |
| Net income from continuing operations | (23) | (68) | (165) | 67 | (349) | 378 | (650) | (154) | (366) | (582) |
| Net income | (23) | (68) | (165) | 67 | (349) | 378 | (650) | (154) | (366) | (582) |
| Net income to common shareholders | – | (68) | (165) | 67 | – | – | – | – | – | – |